Abstract
IMPORTANCE Atopic dermatitis (AD) accounts for a large proportion of the burden of skin disease with a prevalence of around 10% among adults worldwide. In addition, systematic reviews and meta-analyses have found that AD is associated with cancer risk at several sites, if found to be causal this could highlight potential treatment targets to reduce cancer risk.
OBJECTIVE To assess the potential causative link between AD and 14 site-specific cancers in a two-sample Mendelian randomization study.
EXPOSURE Atopic dermatitis
DESIGN, SETTING, AND PARTICIPANTS From the largest genome-wide association study (GWAS) of AD (10,788 cases and 30,047 non-cases), genetic variants highly associated (P < 5E-08) with AD in European population were selected as instrumental variables (IVs). Data from large cancer consortia, as well as the UK Biobank study(n=442,239) and the FinnGen study (n=218,792) were employed to assess genetic associations with 14 site-specific cancers and overall cancer. A set of complementary approaches and sensitivity analyses were carried out to examine the robustness of our results. In addition, associations for the same cancer site from different data sources were combined using meta-analyses.
RESULTS We discovered no strong causal evidence of AD on the risk of overall cancer, with effect estimates close to zero. After Benjamini–Hochberg correction, the inverse weighted method indicated no association of AD on overall cancer risk in both the UK biobank (OR, 1.00; 95%CI, 0.94-1.06; FDR, 0.98) and FinnGen studies (OR, 0.96; 95%CI, 0.92, 1.02; FDR, 0.68). No strong evidence of association was found between genetically predicted AD and the risk of any other site-specific cancers.
CONCLUSIONS AND RELEVANCE Our MR investigation does not support a causal effect of AD on cancer risk. This finding has important implications for the prevention and management of both AD and cancer, as it reduces the concern of potential adverse effects of AD on cancer outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the China National Key RD (or Research and Development) Program (No. 2020AAA0105000 and 2020AAA0105004), the Natural Science Foundation of China (No. 82173328), the Natural Science Foundation of China (No. 81872160), the Natural Science Foundation of China (No. 82072940), the Natural Science Foundation of China (No. 82103047), the Natural Science Foundation of China (No. 82102887), the Beijing Municipal Natural Science Foundation (Key Project) (No. 7191009), the Beijing Municipal Natural Science Foundation (No. 7204293), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-CT-A-012), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-CT-B-044), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2022-I2M-CT-B-087), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2022-JKCS-04), the Beijing Association for Science and Technology's "Golden-Bridge Seed Funding Program" (No. ZZ22027), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2019B03), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2019L07), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2020L01), the 2021 Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) (No. CYSF2115), the Chinese Young Breast Experts Research project (No. CYBER-2021-005), the XianSheng Clinical Research Special Fund of China International Medical Foundation (No. Z-2014-06-2103), and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-Young2021-0017). Sarah Lewis is funded by a Cancer Research UK (C18281/A29019) programme grant (the Integrative 38 Cancer Epidemiology Programme). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All supporting data are included in the manuscript and supplemental files through the MRC Integrative Epidemiology Unit (IEU) Open GWAS database (https://gwas.mrcieu.ac.uk/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
